Key result
Triglyceride-lowering trials must target triglyceride-rich lipoprotein pathophysiology to effectively reduce MACE.
Why the study?
Previous trials of TG-lowering therapies on background statins failed to reduce major adverse cardiovascular events or link TG reduction to event reduction, potentially due to trial design limitations, despite TRLs remaining a source of residual risk.
Answers are grounded in this paper and cite their sources.
Review outlines methodologies for evaluating triglyceride-rich lipoprotein-lowering therapies in cardiovascular disease populations, highlighting strategies for optimizing clinical trial design.
Triglyceride-rich lipoproteins (TRLs) are a source of residual risk in patients with atherosclerotic cardiovascular disease, and are indirectly correlated with triglyceride (TG) levels. Previous clinical trials studying TG-lowering therapies have either failed to reduce major adverse cardiovascular events or shown no linkage of TG reduction with event reduction, particularly when these agents were tested on a background of statin therapy. Limitations in trial design may explain this lack of efficacy. With the advent of new RNA-silencing therapies in the TG metabolism pathway, there is renewed focus on reducing TRLs for major adverse cardiovascular event reduction. In this context, the pathophysiology of TRLs, pharmacological effects of TRL-lowering therapies, and optimal design of cardiovascular outcomes trials are major considerations.
No takes yet. Share an insight, caveat, or question.
Malick et al. (2023) conducted a review in Atherosclerotic cardiovascular disease. Triglyceride-Rich Lipoprotein-Lowering Therapies was evaluated. Optimal clinical trial design for new triglyceride-lowering therapies must account for the pathophysiology of triglyceride-rich lipoproteins to effectively reduce major adverse cardiovascular events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: